Literature DB >> 11292187

Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.

J J Michiels1, W Schroyens, Z Berneman, M van der Planken.   

Abstract

In 16 cases, acquired von Willebrand syndrome (AvWS) and hypothyroidism have been described that occur with each other: 15 women and one man, at a mean age of 32 years, range, 13 to 82 years of age. Activated partial thromboplastin time (APTT) was normal in six patients, and five patients had factor VIII concentration (factor VIIIc) levels in excess of 60%. The bleeding time was prolonged in nine of 13 evaluable patients. Activated partial thromboplastin time was prolonged in seven patients, and five of these had factor VIIIc levels between 18 and 45%, with two patients having levels in excess of 60%. A deficiency of other coagulation factors, including factor VII, V, IX, and X, caused by a generalized diminution in protein synthesis in hypothyroidism, may have contributed to the prolongation of the APTT. The AvWS was very likely type 1 in all cases because of a normal von Willebrand factor antigen/ristocetin cofactor (vWF Ag/RCF) ratio. Acquired von Willebrand syndrome was documented via cross immunoelectrophoresis in three patients and via multimeric analysis of vWF in six patients. A definite diagnosis of AvWS type I has to be confirmed by a normal response to 1-desamino-8-D-arginine vasopressin (DDAVP). Treatment of hypothyroidism with thyroxine was associated with the disappearance of the AvWS and the bleeding diathesis. Decreased factor VIIIc, vWF Ag and vWF RCF levels (50%, 33%, and 36% respectively) before thyroxine treatment increased to normal values (97%, 93%, and 107% respectively) after treatment. The absence of bleeding, or mild bleeding, symptoms, in relation to those more commonly recognized with hypothyroidism, has led to the complication of acquired vWF deficiency being underdiagnosed. Acquired von Willebrand syndrome type I should be considered whenever hypothyroidism is diagnosed and thyroid biopsy or surgery is contemplated. The complete relief of AvWS via treatment of hypothyroidism with thyroxine is the final proof of this association and causal relationship.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292187     DOI: 10.1177/107602960100700206

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  14 in total

Review 1.  Thyroid emergencies.

Authors:  Joanna Klubo-Gwiezdzinska; Leonard Wartofsky
Journal:  Med Clin North Am       Date:  2012-02-17       Impact factor: 5.456

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

Review 3.  Hemostasis and thyroid diseases revisited.

Authors:  M Franchini
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

4.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

Review 5.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 6.  The coagulation system in endocrine disorders: a narrative review.

Authors:  A Squizzato; V E A Gerdes; W Ageno; H R Büller
Journal:  Intern Emerg Med       Date:  2007-07-09       Impact factor: 3.397

7.  Congenital Type III von Willebrand's disease unmasked by hypothyroidism in a Shetland sheepdog.

Authors:  Margaret Scuderi; Lauren Bessey; Elisabeth Snead; Hilary Burgess; Anthony Carr
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

Review 8.  Endometrial haemostasis and menstruation.

Authors:  Joanna Davies; Rezan A Kadir
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

Review 9.  Thyroid hormones and cardiovascular disease.

Authors:  Avais Jabbar; Alessandro Pingitore; Simon H S Pearce; Azfar Zaman; Giorgio Iervasi; Salman Razvi
Journal:  Nat Rev Cardiol       Date:  2016-11-04       Impact factor: 32.419

10.  [Safety and effectiveness of total hip arthroplasty in patients with hypothyroidism].

Authors:  Mingcheng Yuan; Qiang Xiao; Zichuan Ding; Tingxian Ling; Zongke Zhou
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.